S-1/A: United Health Products Files for Resale of 15 Million Shares Amid FDA Review

United Health Products seeks to register 15 million shares for resale by White Lion Capital as it awaits FDA decision on its hemostatic gauze product.

Summary

• United Health Products (UHP) has filed a registration statement for the resale of up to 15,000,000 shares of its common stock by White Lion Capital, LLC.
• These shares are to be issued to White Lion under a Common Stock Purchase Agreement (CSPA).
• UHP has already sold 14,240,000 shares to White Lion under a previous registration, generating approximately $3,000,000 in gross proceeds.
• Approximately $7,000,000 worth of shares remain available for future sales to White Lion under the existing agreement.
• The company is currently awaiting FDA approval for its HemoStyp hemostatic gauze product for internal surgical procedures.
• The FDA issued a Deficiencies Letter with approximately 40 comments and requests for additional information.
• The FDA's review period is paused while UHP addresses these deficiencies.
• UHP's common stock is quoted on the OTCMarkets platform under the symbol UEEC, with a last sale price of $0.17 per share on July 19, 2024.
• The company will not receive any proceeds from the resale of shares by White Lion, but may receive proceeds from the sale of shares to White Lion under the CSPA.
• The company intends to use any proceeds from the CSPA to fund research and development, commercialization efforts, and for general corporate purposes.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there's potential for future revenue through the CSPA and FDA approval, the company faces significant financial challenges, regulatory hurdles, and competitive pressures. The FDA deficiency letter and going concern warning weigh heavily on the sentiment.

Positives

• The company has a Common Stock Purchase Agreement with White Lion Capital, providing a potential source of funding.
• The company's hemostatic gauze technology is protected through patents granted by the U.S. Patent and Trademark Office, which protection currently runs through 2029.
• The company has registered trademarks for several product formats, including HEMOSTYP and BooBoo Strips.
• The company has submitted results of the human clinical trial and other information to the FDA on March 21, 2024.

Negatives

• The company has a history of operating losses and may continue to lose money in the future.
• The company's independent registered public accounting firm has expressed substantial doubt about its ability to continue as a going concern.
• The company is dependent on one hemostatic gauze product to generate income in the future.
• The company has identified various material weaknesses in its internal control over financial reporting which could affect its ability to timely and accurately report its results of operations and financial condition.

Risks

• The market price of the company's stock has been and may continue to be highly volatile.
• The low trading volume of the company's common stock may adversely affect the price of its shares and their liquidity.
• The company may in the future seek to raise funds through equity offerings, which could have a dilutive effect on its common stock.
• There is currently no established market for the company's common stock, and it cannot ensure that one will ever develop or be sustained.
• The company's common stock is deemed a penny stock, which may make it more difficult for investors to sell their shares.
• The company can provide no assurances that the FDA will approve its Class III application for internal surgical procedures in the U.S. market for its HemoStyp product.
• The company will need additional financing to execute its business plan and fund operations, which may not be available.

Future Outlook

The company is evaluating paths to rapidly grow its revenue and profits in all potential market segments, with the objective of maximizing shareholder value. Options under consideration include (i) a sale or merger of the Company with an industry leader in the wound care and surgical device sectors, which may include a pre-sale collaboration on commercialization and distribution and (ii) one or more commercial partnerships with established market participants, without any specific, associated sale or merger transaction.

Industry Context

The wound care products market is concentrated among large and established companies such as Baxter International, Becton Dickinson & Company, Bristol-Myers Squibb Company, Johnson & Johnson and 3M Company, each of which have greater capital and operational resources than United Health Products.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• However, it does mention that the wound care market is dominated by large, established companies like Baxter, Becton Dickinson, Johnson & Johnson, and 3M, which have significantly more resources than UHP.
• This suggests that UHP faces a highly competitive landscape and needs to differentiate itself to gain market share.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings.
• The company's ability to continue as a going concern is uncertain, which could impact stakeholders including employees, creditors, and suppliers.

Next Steps

• The company will address the deficiencies identified by the FDA in the Deficiencies Letter.
• The company will continue to evaluate potential commercial partnerships in anticipation of an FDA decision on its Class III PMA application.
• The company will continue to evaluate paths to rapidly grow its revenue and profits in all potential market segments, with the objective of maximizing shareholder value.

Key Dates

Keywords

hemostatic gauze, White Lion Capital, HemoStyp, FDA approval, common stock, resale, CSPA, UEEC, OTCMarkets, registration statement